Welcome to our dedicated page for Ufp Technologies SEC filings (Ticker: UFPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The UFP Technologies, Inc. (UFPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. UFP Technologies is a contract development and manufacturing organization specializing in single-use and single-patient medical devices, and its filings offer detailed insight into its operations, financial performance, and risk profile in the medical device supply chain.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include information on net sales, gross profit, operating income, net income, segment performance, and non-GAAP measures such as organic sales growth, adjusted operating income, adjusted net income, and adjusted EBITDA. These filings also contain management’s discussion and analysis and risk factor sections that elaborate on topics referenced in the company’s press releases, including customer concentration, acquisition integration, supply chain and labor considerations, and regulatory and market risks.
Stock Titan also surfaces current reports on Form 8-K, where UFP Technologies furnishes earnings press releases and investor presentation materials under items such as Results of Operations and Financial Condition and Regulation FD Disclosure. These 8-Ks link the narrative in press releases to the formal SEC record and often include exhibits with detailed financial tables and reconciliations.
In addition to core periodic and current reports, users can monitor other SEC documents related to UFP Technologies, including any proxy materials and insider transaction reports when available. Stock Titan enhances these filings with AI-powered summaries that explain key sections in plain language, highlight important changes from prior periods, and help readers quickly locate information on topics such as MedTech versus non-medical sales, acquisition impacts, and capital structure.
UFP Technologies director Thomas Oberdorf exercised stock options to acquire 2,864 common shares. He exercised options at an exercise price of $22.02 per share, converting them into the same number of common shares. Following the transaction, he directly holds 12,417 shares of UFP Technologies common stock, and this option grant is fully exercised with no remaining derivative position reported.
UFP Technologies Vice President Jason Holt reported a tax-related share disposition. On March 2, 2026, 478 shares of common stock were withheld at a price of $204.30 per share to cover tax liabilities arising from stock unit awards granted in 2023, 2024 and 2025 that vested on that date. After this withholding, Holt directly owned 8,978 shares of UFP Technologies common stock.
UFP Technologies Senior Vice President Christopher P. Litterio reported a tax‑related share disposition. On March 2, 2026, 815 shares of UFP Technologies common stock at a reference price of $204.30 per share were withheld to cover tax liabilities on stock unit awards granted in 2023, 2024 and 2025 that vested that day. After this tax-withholding disposition, he directly owned 11,977 shares of common stock.
UFP Technologies President Mitchell Rock reported a Form 4 showing a tax-related share disposition. On stock units that vested on March 2, 2026, 2,513 shares of common stock were withheld at $204.30 per share to cover tax liabilities, rather than being sold on the open market. After this withholding, Rock directly owns 36,220 shares of UFP Technologies common stock.
UFP Technologies Chief Financial Officer Ronald J. Lataille had 2,677 shares of common stock withheld on March 2, 2026 to cover tax liabilities tied to stock unit awards granted in 2023, 2024 and 2025. After this tax-withholding disposition, he directly owned 15,898 shares and also held 38,940 shares indirectly.
UFP Technologies CEO Jeffrey R. Bailly reported a Form 4 transaction showing a tax-withholding disposition of company stock rather than an open-market trade. On stock units that vested on March 2, 2026, 9,422 shares of common stock at $204.30 per share were withheld to cover tax liabilities. After this withholding, he directly owns 170,163 shares of UFP Technologies common stock. A footnote adds that he also has an indirect interest in 28,706 shares held by a trust, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
UFP Technologies, Inc. files its annual report describing a fast-growing contract development and manufacturing business focused on single-use and single-patient medical devices for leading global OEMs. Its products support minimally invasive surgery, infection prevention, wound care, orthopedics, wearables and biopharma applications.
The company operates a global footprint of ISO 13485-certified and FDA-registered plants, including major facilities in the U.S., Dominican Republic, Mexico, Puerto Rico, Ireland and Costa Rica. Two customers, Intuitive Surgical SARL and Stryker, accounted for approximately 24.3% and 21.5% of 2025 net sales, while the top ten customers represented 68.8%, underscoring significant customer concentration risk.
Market capitalization held by non‑affiliates was about $1,814,993,392 as of June 30, 2025, based on a $244.16 share price, with 7,713,300 shares outstanding in early 2026. The workforce expanded to 4,846 full‑time employees and 503 temporary workers, reflecting continued scaling.
Key risks highlighted include inflationary cost pressures, supply-chain and raw material dependence, geopolitical and climate-related disruptions, cybersecurity threats, heavy reliance on a few customers, regulatory and ESG developments, and challenges integrating acquisitions. The company discloses a February 2026 cyber incident that disrupted some IT systems but reports operations and financial condition remain materially intact so far.
UFP Technologies has provided an updated investor presentation outlining its MedTech-focused contract manufacturing business, strategy, and financial targets. The company reports annual revenue of $603 million, with about 92% coming from medical technology customers and a market capitalization of roughly $1.7 billion as of February 26, 2026.
The presentation highlights exposure to a $550 billion global medical device market growing around 6%, and a $101 billion medical device CDMO market growing near 10%. Management targets 12–18% revenue growth, 28–31% gross margin, and 17–20% adjusted operating margin over three to five years. Historical gross margins increased from 24.9% in 2020 to 29.1% in 2024, while adjusted operating margin rose from 10.3% to 18.3% over the same period, before measuring 17.1% in 2025.
The materials also show a long-term stock price increase of 9,340% over 20 years through February 12, 2026, and describe a two-pronged growth strategy combining organic expansion in high-growth MedTech niches with acquisitions designed to be accretive within the first year.
UFP Technologies, Inc. has amended its long-term Manufacturing Supply Agreement with strategic medical customer Intuitive Surgical SARL. Through a wholly owned subsidiary, the company entered into Amendment No. 27, effective January 1, 2026.
The amendment extends the agreement’s term by two years through December 31, 2029, materially increases annual minimum volumes for the largest program in 2028 and 2029, adds an additional program, and introduces volume-based pricing tied to minimum purchase thresholds and cost-sharing provisions.
UFP Technologies, Inc. reported a material cybersecurity incident affecting many of its information technology systems, including functions such as billing and label making for customer deliveries. The company detected suspicious activity on or about February 14, 2026 and engaged external cybersecurity advisors to investigate.
UFP Technologies isolated affected systems, removed the third party from its IT environment, and restored access to impacted information in all material respects. Certain company or company-related data appears to have been stolen or destroyed, and some files were exfiltrated. The company is still determining whether sensitive or personal information was involved.
Operations have continued in all material respects, supported by contingency plans and data backups. The company expects a significant portion of direct response costs to be reimbursed through insurance and states that, as of this report, the incident has not had a material impact on its financial systems, operations, or financial condition, nor is it believed reasonably likely to do so.